



The United Laboratories International Holdings Limited

聯邦制藥國際控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 3933)

CLARIFICATION ANNOUNCEMENT

Reference is made to the Company's announcement dated 15 August 2008 in respect of the interim results for the six months ended 30 June 2008 (the "Interim Results Announcement").

Due to inadvertent clerical error, there were mistakes in the presented amount of inter-segment sales of intermediate products for the six months ended 30 June 2008 in note 3 on page 6 of the Interim Results Announcement. The inter-segment sales of intermediate products for the six months ended 30 June 2008 should be HK\$408,540,000 instead of HK\$801,504,000. The segmental turnover (including inter-segment sales) for the six months ended 30 June 2008 should be read as below:

	Intermediate products HK\$'000	Bulk medicine HK\$'000	Finished products HK\$'000	Elimination HK\$'000	Combined HK\$'000
TURNOVER					
External sales	419,040	909,916	642,764	-	1,971,720
Inter-segment sales	408,540	120,947	-	(529,487)	-
	<u>827,580</u>	<u>1,030,863</u>	<u>642,764</u>	<u>(529,487)</u>	<u>1,971,720</u>

The percentage increase in segmental turnover (including inter-segment sales) of intermediate products for the six months ended 30 June 2008 in the first paragraph headed "Business review for the first half of 2008" on page 11 of the Interim Results Announcement should be 114.3% instead of 216.0%.

By Order of the Board
**The United Laboratories
International Holdings Limited**
Leung Wing Hon
Company Secretary

Hong Kong, 19 August 2008

As at the date of this announcement, the Board comprises Mr Choy Kam Lok, Ms Peng Wei and Mr Leung Wing Hon as the executive directors; Ms Choy Siu Chit as non-executive director; and Messrs Heng Kwoo Seng, Huang Bao Guang and Song Ming as independent non-executive directors.